BioLineRx Presents Final Results from Phase 2a Trial for Relapsed/Refractory AML at SOHO Conference
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- Wall St mixed as Middle East tensions eclipse tech strength
- L3Harris CEO steps down amid conduct review, shares drop
- Reddit leads social media platforms in revenue growth per user
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
Roth Positive on BioLineRx (BLRX) Amid Latest BL-8040 Phase 2a Data in r/r AML
September 8, 2016 9:59 AM EDTRoth Capital affirms its Buy rating and $7 price target on BioLineRx Ltd. (Nasdaq: BLRX) after the company announced the presentation of successful final results of BL-8040's Phase 2a clinical trial in relapsed or refractory acute myeloid leukemia (r/r AML).
Analyst Joseph Pantginis commented today, The final r/r AML data continue to point to a bright path forward... More
